Key Highlights
- Needham shifts ARM rating to Buy after two and a half years at Hold, establishing a $200 price objective
- The company introduced its inaugural in-house AGI CPU chip during the “Arm Everywhere” showcase
- Meta Platforms becomes the debut commercial partner for ARM’s new processor technology
- Jefferies increases price objective to $210, forecasting an additional $15B in revenue potential through FY2031
- Latest quarterly results exceeded expectations with $0.43 EPS versus $0.41 consensus and 26.3% revenue growth
On Wednesday, Needham analysts elevated their position on Arm Holdings to Buy after maintaining a neutral outlook for more than two years, establishing a 12-month price objective of $200.
Arm Holdings plc American Depositary Shares, ARM
The investment firm highlighted ARM’s strategic initiatives in the semiconductor space — implementing higher royalty structures, diversifying into subsystem offerings, and launching proprietary chip designs. According to Needham, these strategic moves are beginning to deliver measurable results.
ARM has delivered 26.45% top-line expansion across the trailing twelve-month period. A total of nineteen Wall Street analysts have increased their earnings projections for the forthcoming reporting cycle.
A central element of the upgrade rationale centers on ARM’s silicon market entry via its partnership with Meta Platforms. Meta’s commitment as the inaugural customer for ARM’s proprietary AGI CPU provides the new product with substantial commercial credibility right out of the gate.
The AGI CPU made its official debut during ARM’s “Arm Everywhere” conference. Following this announcement, Jefferies elevated its price objective to $210 from $170, emphasizing the processor’s capacity to contribute $15 billion in incremental revenue by the 2031 fiscal year.
Barclays confirmed its Overweight stance while increasing its target to $200 from $165. The investment bank emphasized the power efficiency characteristics of the AGI CPU architecture as a significant competitive edge for artificial intelligence applications.
BofA Securities increased its objective to $155 from $140 while maintaining a Neutral stance. Morgan Stanley preserved its Overweight rating with a $135 target, acknowledging ARM’s innovative dual-chiplet CPU architecture designed for AI cloud deployments.
Wall Street Sentiment
Current analyst consensus reflects a Moderate Buy recommendation, with a mean price objective of $168.17. This assessment is derived from 19 Buy recommendations, 6 Hold positions, and 1 Sell rating.
ARM’s 50-day moving average currently registers at $120.72, while the 200-day moving average sits at $134.17. The shares have traded within a 52-week band of $80.00 to $183.16, supporting a market capitalization of approximately $165.95 billion.
The stock currently trades at a P/E multiple of 209. According to InvestingPro analysis, the shares are trading above their calculated Fair Value metric.
During the latest reporting period, ARM disclosed earnings per share of $0.43, surpassing Wall Street expectations of $0.41. Total revenue reached $1.24 billion, representing 26.3% year-over-year growth and modestly exceeding the $1.23 billion analyst consensus.
Forward Outlook
ARM issued Q4 FY2026 guidance projecting earnings between $0.54 and $0.62 per share. The analyst community collectively anticipates full-year EPS of $0.90.
Needham emphasized the emergence of agentic artificial intelligence and the expanding significance of CPU architecture in AI infrastructure as sustained growth drivers supporting ARM’s market position.
The AGI CPU targets agentic AI applications, incorporating a multi-core, energy-optimized architecture. Industry observers indicate the processor will require comprehensive software and hardware ecosystem development to effectively challenge established competitors such as Nvidia, Intel, and AMD.
Susquehanna moved ARM from Neutral to Positive in January, setting a $150 price objective. Mizuho reduced its target from $190 to $160 in February while keeping an Outperform recommendation.
Institutional investors currently hold 7.53% of outstanding shares.
